Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siu-Long Yao

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 7, 2023
Response to: "Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis"Eric Peters, Richard C Chou, Stephen J Rozzo, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|May 10, 2023
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing SpondylitisEric Peters, Richard C Chou, Stephen J Rozzo, et al.
European Urology|March 25, 2015
Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate CancerGrace L Lu-Yao, Peter C Albertsen, Dirk F Moore, et al.
JAMA|July 10, 2008
Survival following primary androgen deprivation therapy among men with localized prostate cancerGrace L Lu-Yao, Peter C Albertsen, Dirk F Moore, et al.
JAMA Internal Medicine|July 16, 2014
Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancerGrace L Lu-Yao, Peter C Albertsen, Dirk F Moore, et al.
Dermatology and Therapy|April 30, 2026
Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO<sup>®</sup>)Adilson DaCosta, Cláudio de Lélis Filgueiras de Souza, Renan Minotto, et al.
European Urology|May 22, 2012
Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?Grace L Lu-Yao, Peter C Albertsen, Hui Li, et al.
Journal of Translational Medicine|October 18, 2013
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesJohn J Nemunaitis, Karen A Small, Paul Kirschmeier, et al.
Journal of the American Academy of Dermatology|March 30, 2024
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b studyKurt Gebauer, Lynda Spelman, Paul S Yamauchi, et al.
Parkinsonism & Related Disorders|January 30, 2023
Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's diseaseRyan R Walsh, Nitin K Damle, Sanjay Mandhane, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 7, 2023
Response to: "Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis"Eric Peters, Richard C Chou, Stephen J Rozzo, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|May 10, 2023
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing SpondylitisEric Peters, Richard C Chou, Stephen J Rozzo, et al.
European Urology|March 25, 2015
Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate CancerGrace L Lu-Yao, Peter C Albertsen, Dirk F Moore, et al.
JAMA|July 10, 2008
Survival following primary androgen deprivation therapy among men with localized prostate cancerGrace L Lu-Yao, Peter C Albertsen, Dirk F Moore, et al.
JAMA Internal Medicine|July 16, 2014
Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancerGrace L Lu-Yao, Peter C Albertsen, Dirk F Moore, et al.
Dermatology and Therapy|April 30, 2026
Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO<sup>®</sup>)Adilson DaCosta, Cláudio de Lélis Filgueiras de Souza, Renan Minotto, et al.
European Urology|May 22, 2012
Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?Grace L Lu-Yao, Peter C Albertsen, Hui Li, et al.
Journal of Translational Medicine|October 18, 2013
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesJohn J Nemunaitis, Karen A Small, Paul Kirschmeier, et al.
Journal of the American Academy of Dermatology|March 30, 2024
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b studyKurt Gebauer, Lynda Spelman, Paul S Yamauchi, et al.
Parkinsonism & Related Disorders|January 30, 2023
Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's diseaseRyan R Walsh, Nitin K Damle, Sanjay Mandhane, et al.
Pageof 4